全文获取类型
收费全文 | 56143篇 |
免费 | 6404篇 |
国内免费 | 983篇 |
专业分类
耳鼻咽喉 | 238篇 |
儿科学 | 2017篇 |
妇产科学 | 1169篇 |
基础医学 | 3642篇 |
口腔科学 | 1373篇 |
临床医学 | 8404篇 |
内科学 | 10725篇 |
皮肤病学 | 571篇 |
神经病学 | 4145篇 |
特种医学 | 1059篇 |
外国民族医学 | 1篇 |
外科学 | 5583篇 |
综合类 | 5480篇 |
现状与发展 | 8篇 |
一般理论 | 10篇 |
预防医学 | 9209篇 |
眼科学 | 692篇 |
药学 | 4843篇 |
40篇 | |
中国医学 | 634篇 |
肿瘤学 | 3687篇 |
出版年
2024年 | 126篇 |
2023年 | 1479篇 |
2022年 | 1770篇 |
2021年 | 3481篇 |
2020年 | 3174篇 |
2019年 | 2948篇 |
2018年 | 2888篇 |
2017年 | 2650篇 |
2016年 | 2612篇 |
2015年 | 2383篇 |
2014年 | 4334篇 |
2013年 | 5208篇 |
2012年 | 3243篇 |
2011年 | 3502篇 |
2010年 | 2646篇 |
2009年 | 2511篇 |
2008年 | 2517篇 |
2007年 | 2273篇 |
2006年 | 1999篇 |
2005年 | 1780篇 |
2004年 | 1420篇 |
2003年 | 1194篇 |
2002年 | 1002篇 |
2001年 | 914篇 |
2000年 | 700篇 |
1999年 | 558篇 |
1998年 | 510篇 |
1997年 | 447篇 |
1996年 | 352篇 |
1995年 | 343篇 |
1994年 | 292篇 |
1993年 | 286篇 |
1992年 | 234篇 |
1991年 | 222篇 |
1990年 | 173篇 |
1989年 | 159篇 |
1988年 | 134篇 |
1987年 | 112篇 |
1986年 | 104篇 |
1985年 | 166篇 |
1984年 | 126篇 |
1983年 | 118篇 |
1982年 | 123篇 |
1981年 | 76篇 |
1980年 | 69篇 |
1979年 | 52篇 |
1978年 | 21篇 |
1977年 | 30篇 |
1976年 | 33篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
3.
《American journal of surgery》2023,225(1):198-205
BackgroundLiver resection is commonly performed for hepatic tumors, however preoperative risk stratification remains challenging. We evaluated the performance of contemporary prediction models for short-term mortality after liver resection in patients with and without cirrhosis.MethodsThis retrospective cohort study examined National Surgical Quality Improvement Program data. We included patients who underwent liver resections from 2014 to 2019. VOCAL-Penn, MELD, MELD-Na, ALBI, and Mayo risk scores were evaluated in terms of model discrimination and calibration for 30-day post-operative mortality.ResultsA total 15,198 patients underwent liver resection, of whom 249 (1.6%) experienced 30-day post-operative mortality. The VOCAL-Penn score had the highest discrimination (area under the ROC curve [AUC] 0.74) compared to all other models. The VOCAL-Penn score similarly outperformed other models in patients with (AUC 0.70) and without (AUC 0.74) cirrhosis.ConclusionThe VOCAL-Penn score demonstrated superior predictive performance for 30-day post-operative mortality after liver resection as compared to existing clinical standards. 相似文献
4.
5.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
6.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
7.
8.
9.
10.